Keith Regnante - CHIEF FINANCIAL OFFICER at Keros Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Financial Officer
Issuer Symbol
KROS on Nasdaq
All Insider Reports
All Insider Reports

Keith Regnante - trading volume in the past year for Keros Therapeutics, Inc.

Holdings reported by Keith Regnante for Keros Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 39,261 $641,917 $16.35 18 Feb 2026 Direct
Employee Stock Option (Right to Buy) 60,000 24 Feb 2026 Direct Common Stock

Transactions reported by Keith Regnante for Keros Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.